Cerity Partners
GRCE

Cerity Partners’s Grace Therapeutics GRCE Stock Holding History

Cerity Partners’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.93M Hold
849,055
– – ﹤0.01% 1617
2026
Q1 		$3.93M Buy
849,055
+426,323
+101% +$1.67M 0.01% 1139
2025
Q4 		$1.46M Buy
+422,732
New +$1.34M ﹤0.01% 1514

Other funds holding GRCE

EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Cerity Partners's GRCE Position: Q2 2026 in Review

Cerity Partners held its Grace Therapeutics (GRCE) position steady in Q2 2026 at 849,055 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #1617.

Cerity Partners first reported a position in GRCE in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.93M in Q1 2026. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

  • Cerity Partners held 849,055 shares of Grace Therapeutics worth $1.93M as of Q2 2026.
  • Cerity Partners left its Grace Therapeutics share count unchanged in Q2 2026.
  • Grace Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #1617 holding.
  • Cerity Partners first reported a position in Grace Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Cerity Partners's Grace Therapeutics position peaked at $3.93M in Q1 2026.
  • 33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.